TEDA International Cardiovascular Hospital
泰达国际心血管病医院
Listed for 2 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at TEDA International Cardiovascular Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Lung cancer, Pancreatic cancer, Breast cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Other diseases
Coronary heart disease
冠心病Led 7 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
9 hospitals in Tianjin for coronary heart disease231 hospitals in China for coronary heart disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingComparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07439133
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Tianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led7
- Coronary Flow Reserve Measured by Myocardial Perfusion Imaging in Patients Following Percutaneous Coronary Intervention.
- Feasibility of myocardial blood flow quantification to detect flow-limited coronary artery disease with a one-day rest/stress continuous rapid imaging protocol on cardiac-dedicated cadmium zinc telluride single photon emission computed tomo
- Determination of viable myocardium through delayed enhancement cardiac magnetic resonance imaging combined with 18F-FDG PET myocardial perfusion/metabolic imaging before CABG.
- Prognostic value of myocardial flow reserve measured with CZT cardiac-dedicated SPECT low-dose dynamic myocardial perfusion imaging in patients with INOCA.
- Current trends in optimal medical therapy after PCI and its influence on clinical outcomes in China.
- Clinical prognosis of optimal medical therapy after percutaneous coronary intervention in patients with coronary heart disease.
- Diagnostic analysis of new quantitative parameters of low-dose dynamic myocardial perfusion imaging with CZT SPECT in the detection of suspected or known coronary artery disease.
Chinese-language papers (not in the count)3
- [Diagnostic efficiency and incremental value of myocardial blood flow quantification by CZT SPECT for patients with coronary artery disease].
- [The application status of optimal medical therapy after percutaneous coronary intervention and its influence on prognosis].
- [Study on the correlation between subgroup of blood lipid with degree of coronary artery stenosis in patients with coronary atherosclerotic heart disease].
All its trials on ClinicalTrials.gov, any status9
- Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)
- Evaluate the Clinical Efficacy and Safety of Non-Compliant PTCA Balloon Dilatation Catheter
- Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus
- XTR003 PET Radiotracer for the Detection of Viable Myocardium
- Loop Isolation-based Uploading Pre-conditioning
- Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)
- The EVOLVE China Clinical Trial
- Prospective, Randomized, Multicenter Trial to Assess PROMUS™ Element™ Stent
- Tranexamic Acid in Clopidogrel Exposure to Decrease Hemorrhage and Transfusion
Other diseases
Congenital heart disease
先天性心脏病Led 4 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Tianjin for congenital heart disease207 hospitals in China for congenital heart disease
No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led4
- Anomalous origin of the left coronary artery from the pulmonary artery: The role of CZT camera.
- Anomalous origin of left coronary artery from the pulmonary artery in an adult woman with ischemia and steal phenomena.
- Genetic analysis of the CITED2 gene promoter in isolated and sporadic congenital ventricular septal defects.
- Growth and development of children under 5 years of age with tetralogy of Fallot in a Chinese population.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status2
Getting in touch
Name card to show staff or a driver
泰达国际心血管病医院
TEDA International Cardiovascular Hospital
天津
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.